The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Validating the ELN genetic risk classification in patients with AML treated with aza-ven
In this video, Juan Miguel Bergua-Burgues, MD, Hospital San Pedro de Alcantara, Cáceres, Spain, briefly comments on the validation of the European Leukemia Net (ELN) 2024 genetic risk classification for older patients with acute myeloid leukemia (AML) treated with the hypomethylating agent azacitidine (aza) plus venetoclax (ven). This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a validation of the European Leukemia Net about the risk stratification in patients treated with aza-ven in older patients. We see that the European Leukemia Net can classify this type of patients in three groups. I think that there’s a work in progress about this type of comparison of the European Leukemia Net classification and the new classification of the European Leukemia Net about the classification with rungs and the new scale of mutation about TP53 and KRAS mutation...
This is a validation of the European Leukemia Net about the risk stratification in patients treated with aza-ven in older patients. We see that the European Leukemia Net can classify this type of patients in three groups. I think that there’s a work in progress about this type of comparison of the European Leukemia Net classification and the new classification of the European Leukemia Net about the classification with rungs and the new scale of mutation about TP53 and KRAS mutation. But we think that we support the conclusion of the classification of the European Leukemia Net in order to classify the risk of the patients treated with aza-ven.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
